Recombinant Human LGALS3 protein, His-tagged
Cat.No. : | LGALS3-276H |
Product Overview : | Recombinant Human LGALS3 (Met1-Ile250) protein was fused to His-tag at N-terminus and expressed in human 293 cells (HEK293). |
- Specification
- Gene Information
- Related Products
Description : | Galectin-3 (Gal-3) is also known as LGALS3, 35 kDa lectin, Carbohydrate-binding protein 35 (CBP 35), Galactose-specific lectin 3, Galactoside-binding protein (GALBP), IgE-binding protein, Laminin-binding protein, Mac-2 antigen, Lectin L-29. Galectin-3 is a member of the lectin family. LGALS3/Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. LGALS3/Galectin-3 has been shown to be involved in the following biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis. |
Source : | HEK293 |
Species : | Human |
Tag : | His |
Predicted N Terminal : | Met1 |
Form : | Lyophilized from 0.22 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5. Normally sucrose is added as protectant before lyophilization. |
Molecular Mass : | The protein has a calculated MW of 27.5 kDa. The protein migrates as 35-41 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. |
Protein length : | Met1-Ile250 |
Endotoxin : | Less than 1.0 EU per μg by the LAL method. |
Purity : | >95% as determined by SDS-PAGE. |
Storage : | For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: -20 to -70 centigrade for 12 months in lyophilized state; -70 centigrade for 3 months under sterile conditions after reconstitution. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Gene Name : | LGALS3 |
Official Symbol : | LGALS3 |
Synonyms : | LGALS3; lectin, galactoside-binding, soluble, 3; LGALS2; galectin-3; galectin 3; GALIG; MAC 2; lectin L-29; 35 kDa lectin; MAC-2 antigen; IgE-binding protein; laminin-binding protein; galactose-specific lectin 3; carbohydrate-binding protein 35; L31; GAL3; MAC2; CBP35; GALBP |
Gene ID : | 3958 |
mRNA Refseq : | NM_001177388 |
Protein Refseq : | NP_001170859 |
MIM : | 153619 |
UniProt ID : | P17931 |
Products Types
◆ Recombinant Protein | ||
LGALS3-3043R | Recombinant Rat LGALS3 Protein, His (Fc)-Avi-tagged | +Inquiry |
LGALS3-228H | Recombinant Active Human LGALS3 Protein, His-tagged(N-ter) | +Inquiry |
LGALS3-3622H | Recombinant Human LGALS3 | +Inquiry |
LGALS3-2677H | Recombinant Human LGALS3 protein(91-250 aa), C-His-tagged | +Inquiry |
LGALS3-1290H | Recombinant Human LGALS3 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
LGALS3-4766HCL | Recombinant Human LGALS3 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionLGALS3 has been investigated as a potential diagnostic and prognostic marker in various types of cancer. Its expression levels have been correlated with tumor stage, grade, and patient survival. LGALS3 can be detected in blood, urine, and tissue samples, making it a promising biomarker for non-invasive cancer detection and monitoring. Additionally, LGALS3 expression patterns, subcellular localization, and glycosylation status have been associated with specific cancer subtypes and clinical outcomes, providing insights into disease progression and patient prognosis.
The expression of LGALS3 is regulated at multiple levels, including transcriptional, post-transcriptional, and post-translational regulation. Transcription factors, such as Sp1, AP-1, and NF-κB, bind to the promoter region of the LGALS3 gene and regulate its expression. Epigenetic modifications, including DNA methylation and histone acetylation, can also influence LGALS3 expression. Additionally, microRNAs and RNA-binding proteins can regulate the stability and translation of LGALS3 mRNA. Moreover, various extracellular signals, such as cytokines and growth factors, can modulate LGALS3 expression in a tissue-specific and context-dependent manner.
LGALS3, also known as galectin-3, is a multifunctional protein involved in various cellular processes. It plays a role in cell adhesion, migration, apoptosis, immune response, and inflammation. LGALS3 can interact with glycosylated proteins and lipids, modulating their functions and signaling pathways. It also acts as a receptor for extracellular matrix proteins and plays a role in tissue remodeling. Additionally, LGALS3 has been implicated in cancer progression and metastasis, as well as in the regulation of fibrosis and wound healing.
Targeting LGALS3 has emerged as a potential therapeutic strategy in cancer treatment. Inhibition of LGALS3 expression or activity can impede tumor cell survival, migration, and invasion. Additionally, blocking LGALS3-mediated immune evasion mechanisms could enhance anti-tumor immune responses. Various approaches, such as small molecule inhibitors, antibodies, and gene silencing techniques, have been explored to target LGALS3 in preclinical and clinical studies. However, further research is needed to optimize these strategies and evaluate their efficacy and safety in cancer patients.
LGALS3 plays a critical role in immune response and inflammation. It can modulate the activation and function of immune cells, including macrophages, dendritic cells, and T cells. LGALS3 can promote cell adhesion and migration, facilitating immune cell recruitment to sites of inflammation. It also regulates the production of pro-inflammatory cytokines and chemokines, and can act as a chemoattractant for immune cells. Additionally, LGALS3 can modulate the clearance of apoptotic cells and regulate the resolution of inflammation.
LGALS3 contains a conserved carbohydrate recognition domain (CRD) that allows it to bind to glycosylated proteins and lipids. The CRD is responsible for LGALS3's interaction with specific glycan structures, mediating its diverse functions. LGALS3 also has a N-terminal domain involved in protein-protein interactions and a C-terminal domain that regulates its oligomerization. Moreover, LGALS3 can undergo post-translational modifications, such as phosphorylation and glycosylation, which can affect its localization, stability, and function.
LGALS3 has been implicated in various aspects of cancer progression and metastasis. It can promote tumor cell survival, migration, invasion, and angiogenesis. LGALS3 is involved in the modulation of epithelial-mesenchymal transition (EMT), a process essential for cancer cell metastasis. It also interacts with components of the extracellular matrix, promoting tumor cell adhesion and invasion. Furthermore, LGALS3 can influence immune evasion mechanisms employed by cancer cells, contributing to tumor immune escape and resistance to therapy.
Customer Reviews (3)
Write a reviewMy experimentation flourishes, as if guided by the hands of magic, all thanks to this extraordinary reagent.
Compared to similar products, this reagent demonstrates superior cost-effectiveness, satisfying both in terms of quality and price.
The storage conditions for the reagent are simple and do not require special storage environments.
Ask a Question for All LGALS3 Products
Required fields are marked with *
My Review for All LGALS3 Products
Required fields are marked with *
Inquiry Basket